Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.

Internet Explorer 10, Firefox, Chrome, or Safari.

All COVID-19 updates and resources can be found on the CF Canada website here.

Skip To Content
Volunteer Advocate

Trikafta Can't Wait

Together we are stronger and Cystic Fibrosis Canada is asking the cystic fibrosis (CF) community to once again, raise your voices to get access to the breakthrough drug Trikafta. At this time, we are asking the community to send a letter to the PMPRB echoing our collective concerns. 

The Canadian drug approval process is onerous and slow, and many Canadians living with CF can’t wait for access to Trikafta.

Cystic Fibrosis Canada invites the cystic fibrosis community to join us as we call upon various stakeholders in the Canadian drug approval process to fast track Trikafta and ensure access to this breakthrough drug for the Canadians who need it now. #CFcantwait


The Patented Medicine Prices Review Board (PMPRB) has proposed regulatory guidelines that are impacting access to life-changing CF medicines, especially the break-through drug Trikafta.

Cystic Fibrosis Canada’s position on the newly amended PMPRB guidelines is that there are some provisions that could enable access to Trikafta, however the guidelines are still troubling as they go too far. The first section, changing the basket of comparator countries, does the job of reducing prices. Any additional changes will undermine access to innovative medications and need to stop. Cystic Fibrosis Canada submitted a response to the revised draft guidelines on July 28, 2020.

For more information on the proposed changes to the PMPRB and the impact these changes are having on access to life-changing medicines in Canada, like Trikafta, please visit our PMPRB page.


Cystic Fibrosis Canada is asking the CF community to join us and take action to help Canadians living with cystic fibrosis get access to the break-through drug, Trikafta. Download our letter template so that we can collectively ensure the PMPRB hears our feedback before their stakeholder consultation period ends on August 4th 2020. With every letter sent, our collective voice will get stronger.

Download the letter.

Our recommendations aim to bring Trikafta to Canada now and ensure access to life-changing CF drugs into the future.

Send a letter to the PMPRB and tell them that you support Cystic Fibrosis Canada’s recommendations outlined in the written submission and urge the PMPRB to implement them. Call on the PMPRB to:

Stay tuned over the next few weeks for more actions including an outreach campaign to MPs as we keep relentlessly pushing to get Trikafta to Canada now. Because #CFcantwait!


Watch the recording of Cystic Fibrosis Canada's live Q&A session held on July 30th, 2020 discussing the changes to the PMPRB and what our position is on these changes.